Journal of Clinical Psychopharmacology

03/06/2024

Evidence suggests that compounds with antioxidant properties may have a role in the treatment of patients with depression. Coenzyme Q10 (CoQ10) is a fat-soluble antioxidant and exerts its antioxidant effect by directly neutralizing free radicals or reducing tocopherol and preventing the inhibition of mitochondrial activity because of oxidative stress. A new study published in JCP investigates the effects of oral CoQ10 in patients with depression as an adjunctive treatment. https://journals.lww.com/psychopharmacology/fulltext/2024/05000/discovering_the_potential_value_of_coenzyme_q10_as.6.aspx

30/05/2024

The glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. In our new podcast, the co-author of a guest editorial, “Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry,” Hubertus Himmerich, MD, reviews the implications of GLP-1 drugs for psychiatry and healthcare globally.
🎧 Listen to podcast: https://lnkd.in/dk5nxTDS
📰 Read the article: https://lnkd.in/d4jUFPJv

28/05/2024

Zuranolone is a novel short-course treatment for adult patients with postpartum depression. This phase 1 study assessed the extent of zuranolone transfer into breast milk. https://journals.lww.com/psychopharmacology/pages/articleviewer.aspx?year=9900&issue=00000&article=00252&type=Fulltext



https://www.nbcnews.com/health/mental-health/first-pill-postpartum-depression-reaching-patients-results-rcna153912

Psychiatrists are writing the first prescriptions for zuranolone, which got approved last year.

24/05/2024

Listen to our new podcast episode for a discussion on clinical presentations of recreational misuse and diversion.
🎧 Listen to podcast: https://t.ly/TRBag
📄 Read the article: https://t.ly/ootkK

21/05/2024

New data indicate that dutasteride may be efficacious in reducing heavy drinking in men. Dutasteride is widely used to treat benign prostatic hypertrophy and is an inhibitor of 5-alpha reductase enzymes, which play a central role in the production of 5α-reduced neuroactive steroids. Prior studies indicate that neuroactive steroids mediate some of alcohol's effects.

Read more here: https://journals.lww.com/psychopharmacology/fulltext/2024/05000/randomized_placebo_controlled_clinical_trial_of.5.aspx

21/05/2024

An abstract is unavailable.

20/05/2024

se of this study was to test dutasteride's tolerability and efficacy for reducing drinking. Methods Men (n = 142) with heavy drinking (>24 drinks per week) and a goal to either stop or reduce drinking to nonhazardous levels were randomized to placebo or 1 mg dutasteride daily for 12 weeks. We hypoth...

17/05/2024

Zuranolone is a novel short-course treatment for adult patients with postpartum depression. This phase 1 study assessed the extent of zuranolone transfer into breast milk. https://journals.lww.com/psychopharmacology/fulltext/9900/zuranolone_concentrations_in_the_breast_milk_of.252.aspx

16/05/2024

pression. Coenzyme Q10 (CoQ10) is a fat-soluble antioxidant and exerts its antioxidant effect by directly neutralizing free radicals or reducing tocopherol and preventing the inhibition of mitochondrial activity because of oxidative stress. This study aimed to investigate the effects of oral CoQ10 i...

14/05/2024

The 2023 Mitchell B. Balter Award, which is presented annually to recognize outstanding investigations on topics in pharmacoepidemiology published in the Journal of Clinical Psychopharmacology, goes to the authors of the article titled "Adherence to Psychotropic Medication Before and During COVID-19: A Population-Wide Retrospective Observational Study."

The winning article reported research evaluating the effects of the COVID-19 pandemic on adherence to psychotropic medications. The data were drawn from a claims repository that contains information on health service and medication use for most residents of the province of Manitoba, Canada. Findings in this study highlight that although there were concerns about public health measures restricting access to in-person care, access to medications in Manitoba did not seem to be restricted.

You may find the full paper here: https://journals.lww.com/psychopharmacology/fulltext/2023/07000/adherence_to_psychotropic_medication_before_and.3.aspx

14/05/2024

ducted a prevalent new user cohort study using 2 administrative claims databases in Japan. We included patients with schizophrenia initiated on LAIs and propensity score–matched patients on OA. We compared the risks of psychiatric hospitalization and treatment discontinuation based on hazard ratio...

13/05/2024

d adverse effects associated with antiseizure medications. Without proper treatment, depressed PWEs have increased risks for su***de, strained relationships, lowered seizure control, and impairment in functioning. Our objective was to use the existing literature and insights from our experience in t...

10/05/2024

Tachyphylaxis is a phenomenon described as the loss of response to a medication that was previously effective at an established dose. In our new podcast episode, a case of tachyphylaxis to intravenous (IV) racemic ketamine for treatment-resistant major depression is discussed.
🎧 Listen to podcast: https://t.ly/MJHPk
📖 Read the article: https://t.ly/NsueP

Mayo Clinic

09/05/2024

l courses, interventions, and outcomes after acute ingestion of bupropion via oral, intravenous route, and insufflation. Methods The systematic review was registered with PROSPERO on August 5, 2023. We conducted a systematic literature search on July 30, 2023, utilizing 8 databases with the help of....

08/05/2024

The glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. In our new podcast, the co-author of a guest editorial, “Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry,” Hubertus Himmerich, MD, reviews the implications of GLP-1 drugs for psychiatry and healthcare globally.
🎧 Listen to podcast: https://lnkd.in/dk5nxTDS
📰 Read the article: https://lnkd.in/d4jUFPJv

07/05/2024

An abstract is unavailable.

06/05/2024

An abstract is unavailable.

03/05/2024

Listen to our new podcast episode for a discussion on clinical presentations of recreational misuse and diversion.
🎧 Listen to podcast: https://t.ly/TRBag
📄 Read the article: https://t.ly/ootkK

02/05/2024

Our May/June 2024 issue (Volume 44, issue 3) is now available. Access it online: https://journals.lww.com/psychopharmacology/pages/currenttoc.aspx
Brief synopsis of the new issue from the Journal of Clinical Psychopharmacology Editor-in-Chief is below.

02/05/2024

An abstract is unavailable.

30/04/2024

A total of 113 remitted outpatients with Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) bipolar disorder were recruited. The patients were classified on the basis of their current treatment regimen: 44 patients were receiving a single mood stabilizer, 21 patients were receivin...

30/04/2024